

Appointment of Executive Chairman

Neurotech International Limited (ASX: NTI) ('Neurotech', 'NTI' or 'the Company') is pleased to announce the appointment of Mr Mark Davies as Executive Chairman of the Company, effective 17 August 2026. Mr Davies will transition from his current role as Non-Executive Chairman.

As Executive Chairman, Mr Davies will assume a more active role in the strategic and operational leadership of Neurotech. His responsibilities will include corporate strategy, capital markets and funding initiatives, partnering and licensing activities, investor engagement, governance, and strategic oversight of the Company's clinical and regulatory programs.

The appointment reflects the Company's progression into its next stage of development, with an increased focus on the Phase III program, funding strategy and potential partnering and licensing opportunities.

The material terms of Mr Davies' engagement as Executive Chairman in accordance with ASX Listing Rule 3.16.4 are shown in Appendix 1.

Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, doubleblind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Appendix 1 – Executive Chairman Key Terms

Commencement Date as Executive Chairman	17 August 2026
Term	No fixed term, ongoing until terminated by either party.
Position	Executive Chairman
Services	Mr Davies has been engaged to provide the services usually required of an Executive Chairman of a company of the scale and nature of Neurotech International Limited. Refer above.
Fixed Remuneration	A\$25,000 per month, inclusive of any statutory superannuation contributions, plus GST where applicable
Short or Long Term Incentives	None
Notice Period	Either party may terminate the appointment by providing one month's written notice.